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EVALUATION OF THE in vitro ACTIVITY OF SIX ANTIMICROBIAL
AGENTS AGAINST Neisseria gonorrhoeae
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SUMMARY
Use of antimicrobials for the treatment of gonorrhea started in 1930 with the utilization of sulfonamides. With the years other
drugs were used for its treatment such as penicillin, tetracycline, spectinomycin, and others. Although highly specific in the
beginning, these drugs, with time did not show anymore the expected therapeutic results because of aspects of chromosomal and
plasmid-mediated resistance. The purpose of this study was to evaluate the susceptibility of Neisseria gonorrhoeae strains to six
drugs used for its treatment (penicillin, tetracycline, cefoxitin, thiamphenicol, spectinomycin and ofloxacin) by the determination
of minimal inhibitory concentrations of these drugs. We concluded that drugs, such as cefoxitin, thiamphenicol and spectinomycin
still are excellent pharmacological agents for the treatment of gonorrhea. Penicillin, although still efficient, needs more attention
regarding its use, as well as ofloxacin, because of the emergence of resistant strains. Tetracycline and its derivatives should be
strongly contraindicated for the treatment of gonorrhea.
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Gonorrhea is one of the oldest morbid states of humanity. Urethral
secretions of venereal origin, supposedly gonococcal, were already
reported by the Chinese during Huang Ti’s empire in 2,637 BC. The use
of antimicrobials in its therapy was started in the 1930s with
sulphonamides7. However, in spite of being highly efficient, resistance
to this drug developed rapidly4,11, since resistance mechanisms are favored
by the selective pressure of its massive use15. With the appearance of
penicillin, gonorrhea therapy takes a new course. Although in 1943 this
drug showed to be highly efficient16, already by the end of the decade of
the 1950s several reports pointed to a reduced susceptibility of the
gonococcus to penicillin8,29. Since the beginning of the 1980s, reports of
resistance to other drugs, such as spectinomycin25,26 and the
cephalosporins28 also started to emerge. Thus, a good strategy to fight
against and control of a certain microbial morbidity should foresee an
epidemiological survey program, periodically grading susceptibility
behavior of the etiologic agents, among other procedures. The aim of
this study was to evaluate the present susceptibility through minimal
inhibitory concentration (MIC)13 determination of the six main drugs
used for gonorrhea treatment (penicillin, tetracycline, spectinomycin,
cefoxitin, thiamphenicol and ofloxacin).
MATERIAL AND METHODS
This study was performed with Neisseria gonorrhoeae strains
obtained from patients with acute non-complicated gonorrhea, of both
genders, attended by the Sexually Transmitted Diseases Service of the
School of Public Health, São Paulo University. In the period from
November 2004 to July 2005, 65 strains of Neisseria gonorrhoeae
were isolated. The strains were isolated in modified Thayer-Martin
medium and later identified by direct bacterioscopy with Gram staining;
reaction with cytochrome-oxidase and sugar acidification reaction3,23.
They were also submitted to the chromogenic cephalosporin test for
analysis of beta-lactamase enzyme17. In the studied population 15 strains
were isolated of Neisseria gonorrhoeae producing penicillinase
(NGPP). All strains were submitted to the susceptibility test by the
minimal inhibitory concentration (MIC) test using the method of
dilution in Agar18. The tested drugs were prepared according to the
appropriate techniques1,10, and in a way to obtain the following final
concentrations (in µg/mL): to penicillin, cefoxitin and ofloxacin: 0.125;
0.25; 0.5; 1; 2; 4 and 8 ; to thiamphenicol and tetracycline : 0.125;
0.25; 0.5; 1; 2; 4; 8 and 16 ; to spectinomycin: 7.5; 10; 12.5; 15; 17.5;
20; 32; 64 and 128.
The inocula were prepared from subcultures of each Neisseria
gonorrhoeae, with a 18-24 hours variation in growth in medium under
appropriate conditions23,24. The MIC was established by reading the
lowest concentration required for total inhibition of bacterial growth.
Interpretation of the results, summarized in Table 1, was made according
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to the indications of the National Committee for Clinical Laboratory
Standards (NCCLS)19 (Table 1).
RESULTS
The susceptibility test to penicillin revealed that the 50 non-PPNG
strains presented an intermediate susceptibility and the 15 PPNG strains
showed to be resistant to the drug. Regarding cefoxitin, of the non-
PPNG strains, 49 (98%) were susceptible and one (2%) presented
intermediate susceptibility, while 93.3% of the PPNG strains were
susceptible to this drug.
Regarding thiamphenicol, 76% of the non-PPNG strains showed
to be susceptible and 24% presented intermediate susceptibility; of
PPNG strains only 59.9% showed to be susceptible.
As concerns susceptibility to tetracycline, 10% of the non-PPNG
strains showed to be sensitive, 32% with intermediate susceptibility
and 26% resistant, while all PPNG strains were resistant.
Regarding susceptibility to spectinomycin, among the non-PPNG
strains 92% showed to be susceptible and 8% had an intermediate
susceptibility and, among the PPNG strains 86.4% showed to be
susceptible and 13.3% had an intermediate susceptibility.
As regards ofloxacin, 9% of the non-PPNG strains showed to be
resistant, while all PPNG strains were susceptible to this drug ( Tables
2 and 3).
DISCUSSION
Despite a sharp decline in the incidence of gonococcal infection in
developed countries during the last decade, gonorrhea remains one of
the most common sexually transmitted infections in developing
countries and is a global health problem12. Gonococcal resistance to
antimicrobial agents is an increasing problem in the treatment of
gonorrhea. A high prevalence of plasmid-mediated high-level or a
chromosomaly mediated low-level resistance to penicillin or
tetracycline has been recognized in many countries5,14. By this study,
the results obtained regarding cefoxitin showed that non-PPNG strains
presented their MIC with higher frequency at 0.125 µg/mL, while PPNG
strains showed a higher tolerance towards this drug, presenting a MIC
of 0.5 µg/mL with a higher frequency, followed by 2 µg/mL. Among
the non-PPNG strains, the mean was 0.515 µg/mL, with the PPNG
presenting a mean of 1.616 µg/mL. Thus, a process of tolerance among
the Neisseria gonorrhoeae strains is of concern. These data are similar
to those obtained by DILLON et al.9 and SHIGEMURA et al.22, who
identified, respectively, 100% and 90.8% susceptibility to this drug.
Regarding susceptibility behavior of thiamphenicol, the two studied
populations (non-PPNG and PPNG) presented a homogenous variation.
The mean of 1.625 µg/mL observed among the non-PPNG strains is
represented by 2.384 µg/mL among the PPNG strains.
Concerning spectinomycin, the variation observed among PPNG
strains was higher than that observed among the non-PPNG. We identified
20% of the non-PPNG strains and 13.3% of the PPNG strains to be
resistant to this drug, results that are a little higher than those found by
DILLON et al.9, RAHMAN et al.21 and SHIGEMURA et al.22.
Regarding tetracycline, our results indicate a high percentage of
resistance in both studied populations, with results similar to those of
the literature6,9,22.
Table 1
Interpretation of the results according NCCLS guideline (µg/mL)
Drug tested Sensitive Intermediate Resistant
Penicillin ≤ 0.06 - ≥ 2
Cefoxitime ≤ 2 4 ≥ 8
Thiamphenicol ≤ 2 4 ≥ 8
Tetracycline ≤ 0.25 ≥ 2
Spectinomycin ≤ 32 64 ≥ 128
Ofloxacyn ≤ 0.5 - ≥ 1
Table 2
Distribuition of the 50 non NGPP strains according to MIC of the drugs tested
Drug 0.125 0.25 0.5 1 2 4 12.5 17.5 25.5 32 64 128
 Penicillin N 19 18 12 1
% 38 36 24 2
 Cefoxitin N 34 1 11 3 1
% 68 2 22 6 2
 Thiamphenicol N 3 15 15 5 12
% 6 30 30 10 24
 Tetracycline N 5 24 8 12 1
% 10 48 16 24 2
 Spectinomycin N 1 2 37 6 4
% 2 4 74 12 8
 Ofloxacyn N 2 37 7 1 3
% 4 74 14 2 6
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As far as penicillin is concerned, the non-PPNG strains presented
an intermediated susceptibility, with a tendency to increase in
susceptibility to this drug with time, although the obtained results are
inferior to those found by CHOWDRY et al.6 and SHIGEMURA et
al.22. Regarding ofloxacin, we identified only 8% resistance among
the non-PPNG strains, a much inferior result than those reported in the
world literature, which oscillate between 70% and 90% of
resistance2,20,27, these probably being the first resistant strains identified
in Brazil.
The detection of strains other than NGPPs that were presented with
MIC and that fell in the intermediate classification of sensitivity
between cefoxitime and thiamphenicol, and of NGPP strains with
intermediate MIC of sensitivity between thiamphenicol and
spectinomycin, and strains with MIC above the sensitivity limits to
ofloxacyn, is a warning signal. It reinforces the need for the use of
more rigorous criteria in the prescription of these drugs that, in spite
of still being highly effective in the treatment of gonorrhea, already
present indications in the laboratory that suggest they may also be
heading toward a loss of effectiveness in the treatment of the disease,
with the possibility of allowing the emergence of chromosomal or even
plasmidial resistance to these drugs.
CONCLUSION
In conclusion, drugs like cefoxitin, thiamphenicol, spectinomycin
and ofloxacin constitute, even today, excellent drugs for the treatment
of gonorrhea. Penicillin, in spite of being still efficient, requires more
attention as to its use in view of emergence of resistant strains.
Regarding tetracycline, its use at present is daring and its prescription
should be absolutely contraindicated. In view of the obtained results it
can be concluded that most of the tested drugs presented satisfactory
results in the treatment of gonorrhea.
RESUMO
Avaliação in vitro da atividade de seis drogas antimicrobianas
contra Neisseria gonorrhoeae
A utilização de antimicrobianos no tratamento da gonorréia iniciou-
se em 1930 com a utilização das sulfonamidas. No decorrer dos anos
outras drogas passaram a ser utilizadas em seu tratamento como a
penicilina, tetraciclina, espectinomicina e outras. Embora altamente
eficazes no início, essas drogas, ao longo do tempo, passaram a não
mais apresentar o resultado terapêutico esperado em virtude do
aparecimento de quadros de resistência cromossômica e plasmidial.
Este trabalho teve por objetivo avaliar a sensibilidade de cepas de
Neisseria gonorrhoeae a seis drogas utilizadas no seu tratamento
(penicilina, tetraciclina, cefoxitina, tianfenicol, espectinomicina e
ofloxacina) através da concentração inibitória mínima. Concluimos
que drogas como a cefoxitina, o tianfenicol e a espectinomicina ainda
constituem excelentes fármacos para o tratamento da gonorréia. A
penicilina, embora ainda eficaz, enseja maiores cuidados na sua
utilização, assim como a ofloxacina, frente ao surgimento de cepas
resistentes e, a tetraciclina e seus derivados deve ser sobremaneira
contra-indicada no tratamento da gonorréia.
Table 3
Distribution of the 15 NGPP strains according MIC (µg/mL) of the drugs tested
Drug 0.125 0.25 0.5 1 2 4 7.5 8 12.5 15 17.5 20 64
Penicillin N 15
% 100
Cefoxitin N 1 6 3 4 1
% 6.6 40 20 26.7 6.6
Thianphen N 1 3 5 4
% 6.6 20 33.3 40
Tetracycline N 8 7
% 53.3 46.7
Spectinom N 4 3 1 1 4 2
% 26.6 20 6.6 6.6 26.6 13.3
Ofloxacyn N 10 5
% 66.6 33.3
Table 4
Distribution of the 65 strains of Neisseria gonorrhoeae according sensitivity of
the drugs tested
Non PPNG PPNG
Sensitive Resistant Sensitive Resistant
N % N % N % N %
Penicillin 50 100 15 100
Cefoxitin 50 100 15 100
Thiamph 50 100 15 100
Tetracycline 37 74 13 26 8 53.3 7 46.7
Spectinom 50 100 15 100
Ofloxacyn 46 92 4 8 15 100
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